MaurizioZangariMD

Oncology • Little Rock, AR

Hematologic Oncology

Physician

Join to view full profile

Are you Dr. Zangari?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Connect with colleagues in the same hospital or clinic
You already have 22 invites waiting!
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

Claim this profile

Not you? Find your profile

Office
4301 W Markham St
Slot 816
Little Rock, AR 72205
Phone+1 501-526-2873

Fax+1 501-526-2273
Is this information wrong?

Summary

Dr. Maurizio Zangari, MD is an oncologist in Little Rock, Arkansas. He is currently licensed to practice medicine in Arkansas, Utah, and New York. He is affiliated with UAMS Medical Center.

Education & Training

Icahn School of Medicine at Mount SinaiFellowship, Hematology and Medical Oncology, 1991 - 1995
University of Padua College of MedicineClass of 1980

Certifications & Licensure

AR State Medical License 1994 - 2025
UT State Medical License 2007 - 2014
NY State Medical License 1997 - 1999
PA State Medical License 1993 - 1994
American Board of Internal Medicine Hematology

Clinical Trials

Dexamethasone or Dexamethasone in Combination With Thalidomide as Salvage Therapy Start of enrollment: 1998 Jun 01
Completed
Phase 2
Study of Velcade® and Bone Formation in Patients With Relapsed/Refractory Multiple Myeloma Start of enrollment: 2006 Apr 01
Terminated
Phase 2
UARK 2005-05, Coagulation-Related Effects of Velcade Treatment in Patients With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2005 Aug 01
Completed
Not Applicable
Therapeutic Research in Multiple Myeloma Start of enrollment: 2003 Aug 01
Completed
UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma Start of enrollment: 2008 Jul 01
Active, not recruiting
Phase 3
Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy Start of enrollment: 2009 Mar 01
Active, not recruiting
Phase 2
Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients Start of enrollment: 2009 Oct 01
Terminated
Phase 2
Bone Effect of Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma Start of enrollment: 2010 Jan 01
Terminated
Phase 2
UARK 2009-09 Myeloma Cure Project: Prospective Trial of Indefinite Revlimid Maintenance Versus Observation for Currently Event-Free Patients With Multiple Myeloma Start of enrollment: 2010 Apr 01
Completed
Phase 3
UARK 2013-05 A Study of Autologous Expanded Natural Killer Cell Therapy for Asymptomatic Multiple Myeloma Start of enrollment: 2013 Apr 01
Completed
Phase 2
UARK 2014-08 A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered Trametinib Start of enrollment: 2015 Mar 01
Withdrawn
Phase 2
UARK 2014-21 A Phase II Trial of Oncolytic Virotherapy by Systemic Administration of Edmonston Strain of Measles Virus Start of enrollment: 2015 Mar 01
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

CLO24-090: Demographics and Outcomes of Autologous Stem Cell Transplant Among IgD Multiple Myeloma Patients.
Phillip Farmer, Clyde Bailey, Samer Al-Hadidi, Frits VanRhee, Nishanth Thalambedu, Lakshmi Yarlagadda, Sharmilan Thanendrarajan, Maurizio Zangari, Carolina Schinke> ;Journal of the National Comprehensive Cancer Network. 2024 Apr 5
A Risk Stratification System in Myeloma Patients with Autologous Stem Cell Transplantation.
Wancheng Guo, Christopher Strouse, David Mery, Eric R Siegel, Manit N Munshi, Timothy Cody Ashby, Yan Cheng, Fumou Sun, Visanu Wanchai, Zijun Zhang, Clyde Bailey, Dais...> ;Cancers. 2024 Mar 11
Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study.
Meera Mohan, Jorge Monge, Nishi Shah, Danny Luan, Mark Forsberg, Vineel Bhatlapenumarthi, Metodi Balev, Anannya Patwari, Heloise Cheruvalath, Divaya Bhutani, Sharmilan...> ;Blood Cancer Journal. 2024 Mar 5
Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy ...
Mohan, M., Szabo, A., Patwari, A., Esselmann, J., Patel, T., Bachu, R., Rein, L., Janardan, A., Bhatlapenumarthi, V., Annyapu, E., Skoog, C., Goff, A., Hadidi, S., Rad...> ;Bone Marrow Transplantation. 2024 Feb 15
Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems.
Guo, W., Zhan, Y., Mery, D., Siegel, E., Sun, F., Cheng, Y., Ashby, T., Zhang, Z., Bailey, C., Alapat, D., Peng, H., Hadidi, S., Thanendrarajan, S., Schinke, C., Zanga...> ;Blood Cancer Journal. 2024 Feb 14
1 citations
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth.
Sun, F., Cheng, Y., Wanchai, V., Guo, W., Mery, D., Xu, H., Gai, D., Siegel, E., Bailey, C., Ashby, C., Al Hadidi, S., Schinke, C., Thanendrarajan, S., Ma, Y., Yi, Q.,...> ;Nature Communications. 2024 Jan 19
Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up.
Al Hadidi, S., Bailey, C., Panozzo, S., Cottler-Fox, M., Shaughnessy, J., Zhan, F., van Rhee, F., Thanendrarajan, S., Barlogie, B., Zangari, M., Ababneh, O., Schinke, ...> ;Blood Advances. 2024 Feb 13
Application of R2-ISS risk stratification to patients with multiple myeloma treated with autologous stem cell transplants at UAMS.
Wancheng Guo, Anne Zhan, David E Mery, Manit N Munshi, Oussama Makhoul, Clyde Baily, Maurizio Zangari, Guido Tricot, Hongling Peng, John D Shaughnessy Jr> ;Blood Advances. 2023 Nov 14
BCMA- and CST6-specific CAR T cells lyse multiple myeloma cells and suppress murine osteolytic lesions.
Fumou Sun, Yan Cheng, Jin-Ran Chen, Visanu Wanchai, David E Mery, Hongwei Xu, Dongzheng Gai, Samer Al Hadidi, Carolina Schinke, Sharmilan Thanendrarajan, Maurizio Zang...> ;The Journal of Clinical Investigation. 2024 Jan 2
1 citations
High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma.
Yan Cheng, Fumou Sun, Daisy V Alapat, Visanu Wanchai, David Mery, Wancheng Guo, Huojun Cao, Yuqi Zhu, Cody Ashby, Michael Anton Bauer, Intawat Nookaew, Eric R Siegel, ...> ;Cell Reports. Medicine. 2023 Oct 17
EDNRA-Expressing Mesenchymal Cells Are Expanded in Myeloma Interstitial Bone Marrow and Associated with Disease Progression.
Wen Ling, Sarah K Johnson, Syed J Mehdi, Daisy V Alapat, Michael Bauer, Maurizio Zangari, Carolina Schinke, Sharmilan Thanendrarajan, Frits van Rhee, Shmuel Yaccoby> ;Cancers. 2023 Sep 12
8 citations
The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma.
Lindsay Hammons, Aniko Szabo, Abhishek Janardan, Vineel Bhatlapenumarthi, Evanka Annyapu, Binod Dhakal, Samer Al Hadidi, Sabarinath Venniyil Radhakrishnan, Ravi Narra,...> ;Haematologica. 2024 Mar 1
2 citations
Resolving the spatial architecture of myeloma and its microenvironment at the single-cell level.
Lukas John, Alexandra M Poos, Alexander Brobeil, Carolina Schinke, Stefanie Huhn, Nina Prokoph, Raphael Lutz, Barbara Wagner, Maurizio Zangari, Stephan M Tirier, Jan-P...> ;Nature Communications. 2023 Aug 17
Under-representation of black patients with multiple myeloma in studies supporting International Myeloma Working Group guidelines.
Suhib Fahmawi, Carolina Schinke, Sharmilan Thanendrarajan, Maurizio Zangari, John D Shaughnessy Jr, Fenghuang Zhan, Frits van Rhee, Samer Al Hadidi> ;Journal of Cancer Policy. 2023 Sep 1
Growth and dormancy control of myeloma cells by mesenchymal stem cells.
Syed J Mehdi, Kalyan Ghatak, Wen Ling, Sarah K Johnson, Joshua Epstein, Intawat Nookaew, Maurizio Zangari, Carolina Schinke, Sharmilan Thanendrarajan, Frits van Rhee, ...> ;Leukemia Research. 2023 Oct 1
1 citations
A gene signature can predict risk of MGUS progressing to multiple myeloma.
Fumou Sun, Yan Cheng, Jun Ying, David Mery, Samer Al Hadidi, Visanu Wanchai, Eric R Siegel, Hongwei Xu, Dongzheng Gai, Timothy Cody Ashby, Clyde Bailey, Jin-Ran Chen, ...> ;Journal of Hematology & Oncology. 2023 Jun 29
2 citations
Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor c...
Meera Mohan, Zimu Gong, Timothy Cody Ashby, Samer Al Hadidi, Sharmilan Thanendrarajan, Carolina Schinke, Daisy Alapat, John D Shaughnessy Jr, Fenghuang Zhan, Frits van...> ;Cancer. 2023 Aug 15
1 citations
Variability of definition of high-risk multiple myeloma across phase III clinical trials.
Faris Jamal Abu Za'nouneh, Obada Ababneh, Carolina Schinke, Sharmilan Thanendrarajan, Maurizio Zangari, John D Shaughnessy Jr, Fenghuang Zhan, Frits van Rhee, Samer Al...> ;Ejhaem. 2023 May 1
27 citations
Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis.
Farah Mazahreh, Liyan Mazahreh, Carolina Schinke, Sharmilan Thanendrarajan, Maurizio Zangari, John D Shaughnessy, Fenghuang Zhan, Frits van Rhee, Samer Al Hadidi> ;Blood Advances. 2023 Jul 11
1 citations
Racial Differences in Spinal Cord Compression Related Hospitalizations in Patients with Multiple Myeloma.
Samer Al Hadidi, Deepa Dongarwar, Carolina Schinke, Sharmilan Thanendrarajan, Maurizio Zangari, John D Shaughnessy, Frits van Rhee> ;Clinical Hematology International. 2023 Jun 1
5 citations
Corneal toxicity with belantamab mafodotin: Multi-institutional real-life experience.
Meera Mohan, Lisa E Rein, Nishanth Thalambedu, Yetunde Ogunsesan, Munawwar Hussain, Jaskirat Sethi, Fatima Khan, Sravani Gundarlapalli, Lakshmi Yarlagadda, Binod Dhaka...> ;American Journal of Hematology. 2022 Dec 1
1 citations
Ethnic Disparities in AL Amyloidosis Outcomes Among Hospitalized Patients in the United States.
Samer Al Hadidi, Deepa Dongarwar, Hamisu Salihu, Carolina Schinke, Sharmilan Thanendrarajan, Maurizio Zangari, Frits van Rhee> ;Clinical Hematology International. 2022 Sep 1
23 citations
Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level.
Carolina Schinke, Alexandra M Poos, Michael Bauer, Lukas John, Sarah Johnson, Shayu Deshpande, Luis Carrillo, Daisy Alapat, Leo Rasche, Sharmilan Thanendrarajan, Mauri...> ;Blood Advances. 2022 Nov 22
16 citations
The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states.
Leo Rasche, Carolina Schinke, Francesco Maura, Michael A Bauer, Cody Ashby, Shayu Deshpande, Alexandra M Poos, Maurizio Zangari, Sharmilan Thanendrarajan, Faith E Davi...> ;Nature Communications. 2022 Aug 3
21 citations
Geographic and Racial Disparities in Access to Chimeric Antigen Receptor-T Cells and Bispecific Antibodies Trials for Multiple Myeloma.
Raghad Alqazaqi, Carolina Schinke, Sharmilan Thanendrarajan, Maurizio Zangari, John Shaughnessy Jr, Fenghuang Zhan, Guido Tricot, Frits van Rhee, Samer Al Hadidi> ;JAMA Network Open. 2022 Aug 1
Join now to see all

Hospital Affiliations

UAMS Medical CenterLittle Rock, Arkansas